Breaking news

Moncef Slaoui Under Investigation for “Sexual Harassment” Allegations

Written by FDM

The board of directors of GlaxoSmithKline plc (GSK), the majority shareholder of Galvani Bioelectronics, has announced the dismissal of Dr. Moncef Slaoui as chairman of the board of Galvani, with immediate effect.

The dismissal follows a “letter containing allegations of sexual harassment and inappropriate conduct towards a GSK employee by Dr. Slaoui, which occurred several years ago while he was an employee of GSK”, announces the group in a press release.

Upon receipt of the letter, GSK’s board immediately opened an investigation via an experienced law firm to investigate the allegations, the same source continues.

Christopher Corsico, SVP Development at GSK and current member of the Board of Directors of Galvani, has been appointed as the new Chairman of the Board of Directors of Galvani.

Comments

comments